Stepwise to a cure

Phase IIa data for ABX464 from Abivax S.A.S. are a step in the right direction toward a functional cure, but the company will need to show the therapy can achieve much greater reductions in HIV reservoirs, as well as prevent viral rebound.

The ABX464-004 study met its primary safety endpoint. In addition, an exploratory analysis showed seven of 14 evaluable patients had at least a 25% reduction in HIV reservoirs at day 28 as measured by total HIV DNA in peripheral blood mononuclear cells (PBMCs). The mean reduction in HIV reservoirs was 40%...